Cancer Treatment News and Research

RSS

SoftScan clinical results from a breast cancer treatment monitoring study to be presented at IEEE International Conference

ART Advanced Research Technologies Inc. (ART) (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce that Dr. Gregory Czarnota, MD, PhD, Radiation Oncologist at Odette Cancer Centre, Sunnybrook Health Sciences Centre, will be presenting SoftScan® clinical results from a breast cancer treatment monitoring study, at the IEEE Engineering in Medicine and Biology Society 31st Annual International Conference in Minneapolis, Minn.

5 Sep 2009

Aflac Ford Fusion to sport 13-year-old cancer patient's paint scheme

On September 6(th), at Atlanta Motor Speedway, the No. 99 Aflac Ford Fusion will sport a colorful new look inspired by a 13-year-old patient at the Aflac Cancer Center. Aflac invited children at the Aflac Cancer Center and Blood Disorders Service to "Color Carl's Car" for the Labor Day weekend race.

5 Sep 2009

Researchers study tumor diversity to improve breast cancer treatment

One person's breast cancer is not the same as another person's, because the gene mutations differ in each tumor. That makes it difficult to match the best therapy with the individual patient.

5 Sep 2009

Clinical trial of Cerebroprotein Hydrolysate for Injection completes

Hard to Treat Diseases (the "Company") announced today, that its China based subsidiary Mellow Hope, has just finished (August 2009) the clinical trial of Cerebroprotein Hydrolysate for Injection (Brand name: NUTRIPROTEIN) in India.

5 Sep 2009

HTDS announces closure of Regulation D 504 offering

Hard to Treat Diseases (the "Company") (HTDS.PK) announced today that it has closed its Regulation D, Rule 504 offering and is no longer selling shares of its common stock to accredited investors.

4 Sep 2009

Oncotype DX multigene expression test for breast cancer patients

In an effort to provide breast cancer patients with prompt, critical information about treatment options for use at their first visit with the medical oncologist, a number of leading U.S. surgeons request Genomic Health's Oncotype DX molecular test at the time of surgery or biopsy.

4 Sep 2009

Top cancer hospitals have Elekta solutions for information management

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the current edition of The New England Journal of Medicine (NEJM).

3 Sep 2009

National Cancer Institute awards grant to Receptor Logic for breast cancer research

Receptor Logic, Inc. announced today receipt of a Phase I Small Business Technology Transfer (STTR) Grant from the National Cancer Institute. The grant, entitled “Therapeutic Effectiveness of T-Cell Receptor mimic (TCRm™) Antibodies in Breast Cancer Treatment” will accelerate Investigational New Drug Application enabling studies surrounding lead candidate TCRm antibodies.

3 Sep 2009

Boron-based molecules can be used as new pharmacophores

Chemists and biologists have successfully demonstrated that specially synthesized boron compounds are readily accepted in biologically active enzymes, a move that, they say, is a proof of concept that could lead to new drug design strategies.

3 Sep 2009

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass.

2 Sep 2009

New ARRA-funded research on white blood cell functioning

The American Recovery and Reinvestment Act (ARRA) has provided funding for new research to learn more about how white blood cells work. Jonathan Reichner, PhD, of the department of surgery at Rhode Island Hospital has received a grant from the National Institutes of Health with funding through the American Recovery and Reinvestment Act. Reichner's hope is that the research will lead to new immune-enhancing therapies, with potential implications for improvements in both cancer treatment and controlling inflammation accompanying injury and infection.

2 Sep 2009

MammoSite ML radiation therapy system approved for breast cancer treatment

Hologic, Inc. (Hologic or the Company), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the U.S. Food and Drug Administration (FDA) cleared the Company's 510K application for the MammoSite((R)) ML radiation therapy system.

1 Sep 2009

Circulating endothelial cells play a fundamental role in the development of cancer in children

Endothelial progenitor cells may play a role in the start and progression of metastatic disease in children with cancer, according to study results published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

1 Sep 2009

Fox Chase becomes the seventh cancer center to receive the CEO Cancer Gold Standard accreditation

Fox Chase Cancer Center has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to the health of their employees and family members by certifying their efforts to meet an exceptionally high standard of cancer prevention, screening and care guidelines.

1 Sep 2009

CPRIT releases five cancer research requests after receiving first funding

The Cancer Prevention and Research Institute of Texas (CPRIT) released five cancer research requests for applications (RFA) just three months after receiving its first funding. In May, 2009, the 81st Legislature appropriated $450 million dollars in bond proceeds for the next two years for CPRIT to fund cancer research and prevention grants that will expedite innovation in cancer treatment and expand cancer prevention services in the state.

1 Sep 2009

Bio-Matrix Scientific Group's new opportunities in cancer treatment and intellectual property discussed

Bio-Matrix Scientific Group, Inc. Chairman & CEO David Koos commented on the Company’s new opportunities in stem cell research, cancer treatment and intellectual property.

1 Sep 2009

Natural food compounds may play a vital role in cancer treatment

Research in the Linus Pauling Institute at Oregon State University suggests that some natural food compounds, which previously have been studied for their ability to prevent cancer, may be able to play a more significant role in treating it - working side-by-side with the conventional drugs that are now used in chemotherapy.

1 Sep 2009

Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program

Peregrine Pharmaceuticals, Inc., today announced that noted cancer researcher Bruce Chabner, M.D., will serve as a clinical advisor to the company on the design of clinical trials for the bavituximab cancer program.

31 Aug 2009

Study on basic mechanisms that control fertility in worms may help to know how some woman regain their fertility after cancer treatment

Scientific dogma has long asserted that females are born with their entire lifetime's supply of eggs, and once they're gone, they're gone. New findings by researchers at Fred Hutchinson Cancer Research Center, published online Aug. 27 in Science, suggest that in nematode worms, at least, this does not hold true.

28 Aug 2009

Cancer Treatment News and Research

SoftScan clinical results from a breast cancer treatment monitoring study to be presented at IEEE International Conference

Aflac Ford Fusion to sport 13-year-old cancer patient's paint scheme

Researchers study tumor diversity to improve breast cancer treatment

Clinical trial of Cerebroprotein Hydrolysate for Injection completes

HTDS announces closure of Regulation D 504 offering

Oncotype DX multigene expression test for breast cancer patients

Top cancer hospitals have Elekta solutions for information management

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

National Cancer Institute awards grant to Receptor Logic for breast cancer research

Boron-based molecules can be used as new pharmacophores

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

New ARRA-funded research on white blood cell functioning

MammoSite ML radiation therapy system approved for breast cancer treatment

Circulating endothelial cells play a fundamental role in the development of cancer in children

Fox Chase becomes the seventh cancer center to receive the CEO Cancer Gold Standard accreditation

CPRIT releases five cancer research requests after receiving first funding

Bio-Matrix Scientific Group's new opportunities in cancer treatment and intellectual property discussed

Natural food compounds may play a vital role in cancer treatment

Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program

Study on basic mechanisms that control fertility in worms may help to know how some woman regain their fertility after cancer treatment

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News